medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2019, Number 5

<< Back Next >>

Rev Invest Clin 2019; 71 (5)

Insulin-Like Growth Factor Binding Protein-1, Non-alcoholic Fatty Liver Disease, and its Relationship with Fructose Consumption in Children with Obesity

Flores-Ramírez AG, Ibarra-Reynoso LR, López-Lemus HL, Olvera-Juárez M; Luevano-Contreras C, Garay-Sevilla ME

Language: English
References: 49
Page: 339-348
PDF size: 177.93 Kb.


ABSTRACT

Background: Over consumption of added sugar is associated with obesity, non-alcoholic fatty liver disease (NAFLD), and insulin resistance (IR). Objective: The objective of the study was to study the insulin-like growth factor binding protein-1 (IGFBP-1) and NAFLD and their relationship with fructose consumption in children with obesity. Methods: A cross-sectional study was carried out in children 6-11 years old with obesity. Anthropometric measurements, fructose consumption, glucose, lipid profile, insulin, and IGFBP-1 levels were evaluated; the homeostatic model assessment of IR (HOMA-IR) was used. NAFLD was evaluated by ultrasound. Results: We studied 83 children with a mean age of 9.2 ± 1.3 years. About 93% of the girls presented IR and lower levels of IGFBP-1 (p = 0.0001). The group with the lower levels of IGFBP-1 had higher HOMA-IR (p = 0.000002); IGFBP-1 was associated with fructose consumption (r = −0.25; p = 0.03), body mass index (BMI) (r=−0.42; p = 0.02), and HOMA-IR (r=−0.61; p = 0.002). About 81% of the children were classified as having mild or moderate/ severe NAFLD, and these groups had higher HOMA-IR (p = 0.036) and fructose consumption (p = 0.0014). Conclusions: The girls had more metabolic alterations. The group with lower levels of IGFBP-1 (hepatic IR) was associated with higher BMI, HOMA-IR, and fructose consumption; the group with higher severity of NAFLD showed higher HOMA-IR and fructose consumption.


REFERENCES

  1. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378:804-14.

  2. Hannou SA, Haslam DE, McKeown NM, Herman MA. Fructose metabolism and metabolic disease. J Clin Invest. 2018;128: 545-55.

  3. Bray GA, Popkin BM. Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes? Health be damned! Pour on the sugar. Diabetes Care. 2014;37:950-6.

  4. Ter Horst KW, Schene MR, Holman R, Romijn JA, Serlie MJ. Effect of fructose consumption on insulin sensitivity in nondiabetic subjects: a systematic review and meta-analysis of diet-intervention trials. Am J Clin Nutr. 2016;104:1562-76.

  5. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010; 7:251-64.

  6. Diraison F, Yankah V, Letexier D, Dusserre E, Jones P, Beylot M, et al. Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans. J Lipid Res. 2003; 44:846-53.

  7. Herman MA, Samuel VT. The sweet path to metabolic demise: fructose and lipid synthesis. Trends Endocrinol Metab. 2016; 27:719-30.

  8. Ter Horst KW, Serlie MJ. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients. 2017;9:e981.

  9. Schwarz JM, Noworolski SM, Wen MJ, Dyachenko A, Prior JL, Weinberg ME, et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. J Clin Endocrinol Metab. 2015; 100:2434-42.

  10. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology. 2013;57:2525-31.

  11. Aeberli I, Hochuli M, Gerber PA, Sze L, Murer SB, Tappy L, et al. Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial. Diabetes Care. 2013;36:150-6.

  12. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148:852-71.

  13. Borai A, Livingstone C, Heald AH, Oyindamola Y, Ferns G. Delta insulin-like growth factor binding protein-1 (ΔIGFBP-1): a marker of hepatic insulin resistance? Ann Clin Biochem. 2014; 51:269-76.

  14. Kotronen A, Lewitt M, Hall K, Brismar K, Yki-Jarvinen H. Insulinlike growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab. 2008; 93:4867-72.

  15. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K, et al. Insulin-like growth factor-binding protein-1 in the prediction and development of Type 2 diabetes in middle-aged Swedish men. Diabetologia. 2008;51:1135-45.

  16. Lu J, Liu KC, Schulz N, Karampelias C, Charbord J, Hilding A, et al. IGFBP1 increases β-cell regeneration by promoting α- to β-cell transdifferentiation. EMBO J. 2016;35:2026-44.

  17. Lewitt MS, Hilding A, Brismar K, Efendic S, Ostenson CG, Hall K, et al. IGF-binding protein 1 and abdominal obesity in the development of Type 2 diabetes in women. Eur J Endocrinol. 2010; 163:233-42.

  18. Harrela M, Koistinen R, Tuomilehto J, Nissinen A, Seppala M. Low serum insulin-like growth factor-binding protein-1 is associated with an unfavourable cardiovascular risk profile in elderly men. Ann Med. 2000;32:424-8.

  19. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92:1472-89.

  20. Graffigna M, Belli S, Larranaga G, Fainboim H, Estepo C, Peres S, et al. La proteina transportadora del factor de crecimiento insulinico Tipo 1: Un nuevo marcador para la enfermedad hepatica grasa no alcoholica? Acta Gastroenterol Latinoam. 2009; 39:30-7.

  21. Ibarra-Reynoso Ldel R, Pisarchyk L, Perez-Luque EL, Garay-Sevilla ME, Malacara JM. Whole-body and hepatic insulin resistance in obese children. PLoS One. 2014;9:e113576.

  22. Reinehr T, Kleber M, Toschke AM, Woelfle J, Roth CL. Longitudinal association between IGFBP-1 levels and parameters of the metabolic syndrome in obese children before and after weight loss. Int J Pediatr Obes. 2011;6:236-43.

  23. National Health and Nutrition Examination Survey. Anthropometry Procedures Manual; 2007. Available from: http://www.cdc. gov/nchs/data/nhanes/nhanes_07_08/manual_an.pdf. [Last accessed on 2019 Feb].

  24. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000;320:1240-3.

  25. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-76.

  26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.

  27. Aradillas-Garcia C, Rodriguez-Moran M, Garay-Sevilla ME, Malacara JM, Rascon-Pacheco RA, Guerrero-Romero F, et al. Distribution of the homeostasis model assessment of insulin resistance in Mexican children and adolescents. Eur J Endocrinol. 2012;166:301-6.

  28. Quijada Z, Paoli M, Zerpa Y, Camacho N, Cichetti R, Villarroel V, et al. The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. Pediatr Diabetes. 2008;9:464-71.

  29. Yoo DY, Kang YS, Kwon EB, Yoo EG. The triglyceride-to-high density lipoprotein cholesterol ratio in overweight Korean children and adolescents. Ann Pediatr Endocrinol Metab. 2017; 22:158-63.

  30. Pollock NK, Bundy V, Kanto W, Davis CL, Bernard PJ, Zhu H, et al. Greater fructose consumption is associated with cardiometabolic risk markers and visceral adiposity in adolescents. J Nutr. 2012;142:251-7.

  31. Mittelstaedt CA. General Ultrasound. 1st ed. New York: Churchill Livingstone; 1992.

  32. Campos VC, Tappy L. Physiological handling of dietary fructosecontaining sugars: implications for health. Int J Obes (Lond). 2016;40 Suppl 1:S6-11.

  33. Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90:23-46.

  34. Bernardo AP, Oliveira JC, Santos O, Carvalho MJ, Cabrita A, Rodrigues A, et al. Insulin resistance in nondiabetic peritoneal dialysis patients: associations with body composition, peritoneal transport, and peritoneal glucose absorption. Clin J Am Soc Nephrol. 2015;10:2205-12.

  35. Rajwani A, Ezzat V, Smith J, Yuldasheva NY, Duncan ER, Gage M, et al. Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes. 2012;61:915-24.

  36. Hellerstein MK, Schwarz JM, Neese RA. Regulation of hepatic de novo lipogenesis in humans. Annu Rev Nutr 1996;16:523-57.

  37. Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin- like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016;14:3.

  38. Lewitt MS, Dent MS, Hall K. The insulin-like growth factor system in obesity, insulin resistance and Type 2 diabetes mellitus. J Clin Med. 2014;3:1561-74.

  39. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015;10:e0140908.

  40. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-52.

  41. Nagai Y, Yonemitsu S, Erion DM, Iwasaki T, Stark R, Weismann D, et al. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab. 2009;9:252-64.

  42. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2011; 108:16381-5.

  43. Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes M, Bertrand-Michel J, et al. The lipogenic transcription factor chREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest. 2012;122:2176-94.

  44. Farese RV Jr., Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab. 2012;15:570-3.

  45. Stanhope KL, Schwarz JM, Havel PJ. Adverse metabolic effects of dietary fructose: Results from the recent epidemiological, clinical, and mechanistic studies. Curr Opin Lipidol. 2013;24:198- 206.

  46. Cascales M. Lipogenesis de novo y Termogenesis. Available from: http://www.analesranf.com/index.php/mono/article/ download/1571/1655. [Last accessed on 2019 Feb].

  47. Gugliucci A. Formation of fructose-mediated advanced glycation end products and their roles in metabolic and inflammatory diseases. Adv Nutr. 2017;8:54-62.

  48. Ibarra-Reynoso LD, Lopez-Lemus HL, Garay-Sevilla ME, Malacara JM. Effect of restriction of foods with high fructose corn syrup content on metabolic indices and fatty liver in obese children. Obes Facts. 2017;10:332-40.

  49. Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, et al. Noninvasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 2010; 52:579-85.




2020     |     www.medigraphic.com